Shenzhen EFUNG Investment Management Enterprise is an institution that invests in professional biomedical industries.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Shenzhen EFUNG Investment Management Enterprise L. P. is one of China&s;s earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won &s;The Most Pioneering VC Institution” &s;The Most Dynamic Pharmaceutical VC Institution in China&s; and &s;The Top Ten VC Institutions in Shenzhen&s;. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
6/2018 | Chipscreen | Venture Round | - |
1/2022 | West Lake Omi | Seed Round | - |
5/2010 | Rainjet | Series A | 1.5M |
7/2019 | TriArm Therapeutics | Series A | 0 |
4/2020 | SiBionics | Series B | 28.4M |
6/2018 | Centrexion | Venture Round | - |
12/2021 | BioInno | Series A | - |
3/2022 | CellOrigin Biotech | Venture Round | 0 |
1/2023 | JGene Biotechnology | Angel Round | - |
7/2012 | UNIHZ TECHNOLOGY | Angel Round | 469.6k |
11/2020 | Biostar Technologies | Series E | 890M |
3/2021 | Gensciences | Series B | - |
1/2022 | Cloudbreak Therapeutics | Series C | 0 |
2/2023 | Turno | Series A | 0 |
8/2015 | Ascentage Pharma | Series A | 15.5M |
12/2022 | Maijing Gene | Series C | - |
11/2021 | JGene Biotechnology | Angel Round | - |
1/2022 | Atom Bioscience &a; Pharmaceutical | Series C | 45M |
1/2018 | KBP Biosciences | Series A | 0 |
12/2021 | Kind Pharmaceutical | Series B | 50M |
3/2020 | OBiO Technology | Series B | 15M |
3/2020 | Harbour Biomed | Series B | 75M |
6/2018 | Frontier Biotechnologies | Venture Round | - |
6/2018 | Resverlogix | Post-IPO Equity | 10.4M |
6/2018 | Lifotronic | Venture Round | - |
11/2022 | Trinomab | Venture Round | 104.7M |
7/2020 | OBiO Technology | Series C | 28.5M |
12/2020 | Raynovent | Series B | 42.8M |
12/2021 | XuanZhu Pharma | Series B | 0 |
7/2020 | InnerMedical | Series B | - |
12/2021 | CirCode | Seed Round | 20M |
7/2019 | Zhongyianke Biotech | Series A | 36M |
12/2018 | Tactiva Therapeutics | Series A | 35M |
9/2020 | Jifu Medical | Series C | 0 |
10/2019 | WeMed | Series C | - |
6/2018 | Aridis Pharmaceuticals | Venture Round | - |
10/2019 | Elicio Therapeutics | Series B | 33M |
1/2023 | IASO Biotherapeutics | Series C | 73.8M |
1/2023 | Raynovent | Series C | 53.8M |
5/2022 | JSD | Series A | - |
10/2020 | 3D Medicines | Venture Round | 0 |
11/2012 | Castdservo | Angel Round | 481.6k |
2/2022 | JGene Biotechnology | Seed Round | - |
5/2022 | JSD | Series A | - |
3/2022 | CellOrigin Biotech | Venture Round | 0 |
1/2022 | West Lake Omi | Seed Round | - |
1/2022 | Atom Bioscience &a; Pharmaceutical | Series C | 0 |
1/2022 | Cloudbreak Therapeutics | Series C | 0 |
12/2021 | XuanZhu Pharma | Series B | 0 |
12/2021 | Kind Pharmaceutical | Series B | 0 |
12/2021 | BioInno | Series A | - |
12/2021 | CirCode | Seed Round | 0 |
11/2021 | JGene Biotechnology | Angel Round | - |
Name | Price |
---|
Name | Size | Announced Date |
---|